FDA delays decision on abortion drug mifepristone until October

Federal district court ordered the FDA to report on its mifepristone safety review by October 7, 2026, pausing Louisiana's lawsuit while the Trump administration conducts its examination.

Objective Facts

The Louisiana district court gave the FDA until October 7, 2026—one month before the midterms—to file a status report on its mifepristone safety review and any updated completion timeframe. The court paused the Louisiana lawsuit for six months while the FDA conducted an internal review of the drug's safety. The Trump administration, which supports abortion restrictions, has relied on HHS Secretary Kennedy and FDA Commissioner Makary's letter citing a methodologically flawed report from a conservative anti-abortion organization to justify the review. Senator Josh Hawley, frustrated with the pace, introduced legislation to rescind FDA approval and launched investigations into drug manufacturers claiming adverse events are underreported. Former Biden HHS official Sam Bagenstos argued the timing suggests the Trump administration wants to avoid restricting access before elections but intends to afterward.

Left-Leaning Perspective

Senate Democrats, led by Senator Ruben Gallego in a letter to HHS Secretary Kennedy and FDA Commissioner Makary, expressed alarm over the Trump administration's "own review of the evidence" on mifepristone, stating they are "alarmed by the Department's obvious attempts to politicize the review, regulation, and approval of mifepristone at the FDA". The senators argued the administration is "blatantly undermining well-established science and weaponizing disinformation to fit the Trump administration's clear agenda to cut off abortion access," specifically criticizing HHS and FDA reliance on the Ethics and Public Policy Center's report. Democrats emphasized that "decades of evidence and hundreds of studies prove the safety and efficacy of mifepristone," characterizing the review as a politically motivated effort to restrict access. Former Biden administration HHS General Counsel Sam Bagenstos noted that while the administration wants to avoid restricting access before midterms to prevent political fallout, "they are doing everything they can to preserve their ability to take access to mifepristone away from women across the country as soon as they're out of the woods". Senate Minority Leader Chuck Schumer called Senator Hawley's complementary ban bill "inconceivably cruel and radical," while Planned Parenthood Action Fund President Alexis McGill Johnson alleged Hawley's "ultimate goal" is "ending access to abortion for everyone, everywhere".

Right-Leaning Perspective

Senator Josh Hawley, dissatisfied with the pace of the FDA review, introduced the Safeguarding Women from Chemical Abortion Act, which would rescind the FDA's approval of mifepristone. Hawley sent a letter to FDA Commissioner Makary accusing him of delaying the promised safety review until after the midterms, calling the situation "totally unacceptable" and emphasizing "the danger of playing politics with women's health". Hawley cited a study showing 11 percent of women taking mifepristone experience serious adverse health effects including "internal infections, sepsis, a trip to the emergency room, a life-threatening condition," though the study from the Ethics and Public Policy Center has been disputed by fact-checkers, while the FDA puts serious adverse effect rates at 0.5 percent. Susan B. Anthony Pro-Life America's communications director Kelsey Pritchard criticized Trump administration inaction, stating "it's just really hard for us to understand how the Trump administration has been so negligent as to leave this policy in place" and reiterated calls for FDA Commissioner Makary's firing. Hawley argued that the widespread availability of mifepristone through mail order has undermined the Supreme Court's 2022 Dobbs decision by allowing people to circumvent state abortion restrictions, regardless of state law. Anti-abortion groups expressed frustration that "the Trump administration's inaction has stopped pro-life laws from taking effect," forcing them to pursue litigation instead.

Deep Dive

The Trump administration's decision to launch an FDA safety review was driven by HHS Secretary Kennedy and FDA Commissioner Makary, citing a report from the Ethics and Public Policy Center—a conservative anti-abortion organization. However, this report has been denounced by over 260 expert researchers as methodologically flawed and unreliable. Mifepristone has been approved since 2000 and decades of studies have conclusively proven its safety, and it is far more heavily regulated than 99.5% of other prescription drugs. The transition from a Biden administration that embraced reproductive rights to a Trump administration that supports abortion restrictions could mark a shift in the FDA's regulatory approach. Former Biden HHS General Counsel Sam Bagenstos argued the administration doesn't want to restrict mifepristone before the midterms due to political liability but plans to preserve the ability to do so afterward. Meanwhile, anti-abortion activists expressed fury at the Trump administration for not acting more aggressively, with Susan B. Anthony Pro-Life America calling for FDA Commissioner Makary's firing and accusing the administration of negligence. The dynamic forced several Republican attorneys general to pursue litigation independently because "the Trump administration's inaction has stopped pro-life laws from taking effect". The October 7 deadline creates a compressed timeline for the FDA to either complete or substantially demonstrate progress on its review. The district court emphasized that the FDA is best equipped to evaluate scientific evidence, with courts serving as a check to ensure the agency fulfills its statutory responsibilities. Left-leaning observers view the October 7 deadline as either allowing the Trump administration to delay substantive restrictions until after elections, while right-wing anti-abortion activists view the deadline as enabling further delay. The Supreme Court's pending decision on the Fifth Circuit's May 1 ruling could preempt the FDA review timeline entirely.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

FDA delays decision on abortion drug mifepristone until October

Federal district court ordered the FDA to report on its mifepristone safety review by October 7, 2026, pausing Louisiana's lawsuit while the Trump administration conducts its examination.

May 9, 2026
What's Going On

The Louisiana district court gave the FDA until October 7, 2026—one month before the midterms—to file a status report on its mifepristone safety review and any updated completion timeframe. The court paused the Louisiana lawsuit for six months while the FDA conducted an internal review of the drug's safety. The Trump administration, which supports abortion restrictions, has relied on HHS Secretary Kennedy and FDA Commissioner Makary's letter citing a methodologically flawed report from a conservative anti-abortion organization to justify the review. Senator Josh Hawley, frustrated with the pace, introduced legislation to rescind FDA approval and launched investigations into drug manufacturers claiming adverse events are underreported. Former Biden HHS official Sam Bagenstos argued the timing suggests the Trump administration wants to avoid restricting access before elections but intends to afterward.

Left says: Senate Democrats accuse the Trump administration of weaponizing a methodologically flawed conservative report to justify restricting a drug proven safe for decades. They argue the administration is delaying action until after elections while planning to restrict access once the midterms pass.
Right says: Senator Josh Hawley, dissatisfied with the FDA review pace, introduced the Safeguarding Women from Chemical Abortion Act to rescind FDA approval of mifepristone. He accused the administration of delaying the promised safety review until after the midterms, calling this "totally unacceptable".
✓ Common Ground
Both the district court and various legal observers across viewpoints recognize that the FDA is best equipped to evaluate scientific evidence regarding mifepristone, with courts serving as a check on agency responsibilities rather than replacing them.
Several voices across the aisle acknowledge that the October 7 deadline creates pressure on the Trump administration to complete or substantially advance the review before the midterm elections, though they disagree on whether delay or expedited action serves public interest.
There appears to be broad recognition that mifepristone has been approved since 2000, has undergone decades of testing, and is far more heavily regulated than other prescription drugs with similar safety profiles.
Objective Deep Dive

The Trump administration's decision to launch an FDA safety review was driven by HHS Secretary Kennedy and FDA Commissioner Makary, citing a report from the Ethics and Public Policy Center—a conservative anti-abortion organization. However, this report has been denounced by over 260 expert researchers as methodologically flawed and unreliable. Mifepristone has been approved since 2000 and decades of studies have conclusively proven its safety, and it is far more heavily regulated than 99.5% of other prescription drugs.

The transition from a Biden administration that embraced reproductive rights to a Trump administration that supports abortion restrictions could mark a shift in the FDA's regulatory approach. Former Biden HHS General Counsel Sam Bagenstos argued the administration doesn't want to restrict mifepristone before the midterms due to political liability but plans to preserve the ability to do so afterward. Meanwhile, anti-abortion activists expressed fury at the Trump administration for not acting more aggressively, with Susan B. Anthony Pro-Life America calling for FDA Commissioner Makary's firing and accusing the administration of negligence. The dynamic forced several Republican attorneys general to pursue litigation independently because "the Trump administration's inaction has stopped pro-life laws from taking effect".

The October 7 deadline creates a compressed timeline for the FDA to either complete or substantially demonstrate progress on its review. The district court emphasized that the FDA is best equipped to evaluate scientific evidence, with courts serving as a check to ensure the agency fulfills its statutory responsibilities. Left-leaning observers view the October 7 deadline as either allowing the Trump administration to delay substantive restrictions until after elections, while right-wing anti-abortion activists view the deadline as enabling further delay. The Supreme Court's pending decision on the Fifth Circuit's May 1 ruling could preempt the FDA review timeline entirely.

◈ Tone Comparison

Democrats use language like "blatantly undermining," "weaponizing disinformation," and "partisan, sham report" to convey the administration is acting in bad faith using false science. Republicans employ dramatic clinical language ("sepsis," "life-threatening") and moral intensity phrasing ("totally unacceptable," "danger of playing politics with women's health") to convey urgency and suggest calculated political delay.